PIC-SURE: an open-source platform for integrating clinical and genomic data
npj Digital Medicine, Published online: 30 December 2025; doi:10.1038/s41746-025-02284-9
PIC-SURE: an open-source platform for integrating clinical and genomic datanpj Digital Medicine, Published online: 30 December 2025; doi:10.1038/s41746-025-02284-9
PIC-SURE: an open-source platform for integrating clinical and genomic dataCell Death Discovery, Published online: 29 December 2025; doi:10.1038/s41420-025-02917-8
Modeling hepatocellular carcinoma and its microenvironment on a chipnpj Digital Medicine, Published online: 30 December 2025; doi:10.1038/s41746-025-02252-3
Computational network models for forecasting and control of mental health trajectories in digital applicationsFront Endocrinol (Lausanne). 2025 Dec 11;16:1676021. doi: 10.3389/fendo.2025.1676021. eCollection 2025.
ABSTRACT
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of tumors characterized by diverse biological behaviors and variable clinical outcomes. Recent advances have highlighted the important role of metabolic reprogramming in tumorigenesis, progression, and therapeutic resistance in GEP-NENs. In this review, we synthesize the current evidence on metabolic biomarkers and altered metabolic pathways-particularly those involving glucose, lipid, and amino acid metabolism. Key biomarkers such as GLUT-1, FASN, and enzymes involved in ferroptosis, cholesterol biosynthesis, and amino acid catabolism demonstrate strong associations with tumor aggressiveness, hypoxia, and mTOR signaling. Moreover, metabolomic profiling and functional studies suggest that metabolic markers may inform prognosis and predict response to targeted therapies such as Everolimus. Although promising, the clinical translation of these markers is still limited and requires further validation in large, subtype-specific cohorts. Our findings highlight the importance of integrating metabolic profiling into the diagnostic and therapeutic landscape of GEP-NENs. Future research should prioritize biomarker standardization, multi-omics integration, and the development of metabolism-based therapeutic strategies tailored to tumor subtype and differentiation grade.
PMID:41458541 | PMC:PMC12738315 | DOI:10.3389/fendo.2025.1676021
Nature Medicine, Published online: 29 December 2025; doi:10.1038/s41591-025-04027-5
An analysis of 204 countries estimates that diabetes will cost the global economy $10.2 trillion between the years 2020 and 2050.npj Digital Medicine, Published online: 27 December 2025; doi:10.1038/s41746-025-02253-2
Context matching is not reasoning when performing generalized clinical evaluation of generative language modelsnpj Digital Medicine, Published online: 26 December 2025; doi:10.1038/s41746-025-02277-8
A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains